Neurocrine Biosciences | Actif À Court Terme



Current Assets Changement Date
AbbVie USD 27.68B 2.09B 2025-03
Acadia Pharmaceuticals USD 960.55M 89.61M 2025-06
Agios Pharmaceuticals USD 1.02B 50.85M 2025-06
ALKERMES USD 1.64B 156.24M 2025-06
Alnylam Pharmaceuticals USD 3.64B 375.44M 2025-06
Amgen USD 26.73B 195M 2025-06
Biogen USD 7.97B 341.7M 2025-06
BioMarin Pharmaceutical USD 3.81B 337.43M 2025-06
Cytokinetics USD 886.54M 69.51M 2025-06
Dynavax Technologies USD 785.71M 30.26M 2025-06
Exelixis USD 1.18B 215.74M 2025-07
Gilead Sciences USD 14.72B 2.18B 2025-06
Halozyme Therapeutics USD 1.12B 139.35M 2025-06
Incyte USD 3.64B 411.91M 2025-06
Ionis Pharmaceuticals USD 2.58B 158.22M 2025-06
Neurocrine Biosciences USD 1.75B 111M 2025-06
Pfizer USD 43.7B 2.16B 2025-06
Prothena USD 485.41M 49.57M 2024-12
Regeneron Pharmaceuticals USD 16.86B 712.2M 2025-06
Repligen USD 1.03B 33.58M 2025-03
Sarepta Therapeutics USD 2.66B 224.45M 2025-06
Teva Pharmaceutical Industries USD 12.62B 1.09B 2025-06
Ultragenyx Pharmaceutical USD 719.79M 20.63M 2025-06
Vertex Pharmaceuticals USD 10.43B 419.1M 2025-06


Neurocrine Biosciences Actif À Court Terme - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Aug 2025.